source
- Bristol Myers reports Phase 3 data showing mezigdomide extends survival in relapsed multiple myelomaBristol Myers Squibb presented Phase 3 results for its experimental multiple myeloma drug mezigdomide at the American Society of Clinical Oncology meeting. The study evaluated mezigdomide combined…
- Pfizer partners with China's Innovent Biologics on $10 billion cancer drug collaborationPfizer announced a major partnership with Chinese biotech Innovent Biologics, valued at over $10 billion, to develop cancer therapies. The agreement covers up to 12 antibody-based candidates, incl…